EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...

(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

3, 2025 — Much of our knowledge of the protein PD-1, a leading cancer treatment target ... in the most common form of pancreatic cancer, according to a new ... Advanced Imaging Uncovers Hidden ...

Autonomix Medical shares were up 24% to $4.10 after the company said it received a patent from the U.S. Patent and Trademark Office.

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Shares of Immuneering Corporation (NASDAQ:IMRX) surged 55% following the release of encouraging data from its ongoing Phase 2a trial of IMM-1-104, a therapy for pancreatic cancer. The Cambridge-based ...